TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24850775

Group type: EXPERIMENTAL
Intervention: 15 mL of 0.2% chlorhexidine (CHX) for 60 s as a rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15 mL of 0.2% chlorhexidine (CHX) for 60 s as a swab
Number of subjects: 0
Study: 24060277

Group type: EXPERIMENTAL
Intervention: Blue lupin fibre (25 g/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: White lupin fibre (25 g/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Soya fibre (25 g/d)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Citrus fibre (25 g/d)
Number of subjects: 92
Study: 21288325

Group type: EXPERIMENTAL
Intervention: Standard treatment plus high-dose rifampicin (15 mg/kg/day) and levofloxacin
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard Vietnamese national guideline treatment for tuberculous meningitis
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Standard treatment plus high-dose rifampicin and levofloxacin
Number of subjects: 750
Study: 19424750

Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study: 22986471

Group type: EXPERIMENTAL
Intervention: Eptifibatide (EG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study: 15800226

Group type: EXPERIMENTAL
Intervention: Warfarin (target international normalized ratio, 2.0 to 3.0)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Aspirin (1300 mg per day)
Number of subjects: 569
Study: 12853534

Group type: EXPERIMENTAL
Intervention: Chlorhexidine silver sulfadiazine (CSS) CVC
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Rifampin-minocycline (RM) CVC
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Uncoated CVC
Number of subjects: 1000
Study: 10568210

Group type: EXPERIMENTAL
Intervention: Lem1 (natural compound derived from lemon oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 8550648

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Morphine and Methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 0
Study: 2191764

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus tamoxifen (RT-TAM)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen (CT-TAM)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 427

Group type: COMPARATOR
Intervention: Radiation therapy or tamoxifen
Number of subjects: 427
Study: 34186

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clorazepate (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa (1000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone (TRH) (2 mg)
Number of subjects: 0
Study: 30135176

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy with engineered multispecificity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approaches to overcome antigen escape
Number of subjects: 0
Study: 26386751

Group type: EXPERIMENTAL
Intervention: Blood control peripheral intravenous catheter
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard peripheral intravenous catheter
Number of subjects: 152
Study: 25802955

Group type: EXPERIMENTAL
Intervention: MT + MG
Number of subjects: 48

Group type: COMPARATOR
Intervention: MT + sham
Number of subjects: 48

Group type: COMPARATOR
Intervention: MT
Number of subjects: 48
Study: 23649374

Group type: EXPERIMENTAL
Intervention: Amiloride, 1 mmol/l, perfused for 5 min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study: 20936369

Group type: EXPERIMENTAL
Intervention: 9c,11t-CLA
Number of subjects: 22

Group type: COMPARATOR
Intervention: 10t,12c-CLA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oleic acid (9c-18:1)
Number of subjects: 22
Study: 18804084

Group type: EXPERIMENTAL
Intervention: Evidence-based curriculum for computer and Internet skills
Number of subjects: 0
Study: 16647411

Group type: EXPERIMENTAL
Intervention: anti-D immune globulin at 75 microg/kg (anti-D75)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: anti-D immune globulin at 50 microg/kg (anti-D50)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: intravenous immune globulin (IVIg) at 0.8 g/kg
Number of subjects: 105
Study: 12540113

Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (Opalescence Quick)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (Opalescence Xtra)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (distilled water at 37 degrees C)
Number of subjects: 27
Study: 10966281

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperventilation (HV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of iNO and HV
Number of subjects: 12
Study: 8613834

Group type: EXPERIMENTAL
Intervention: Women with aneurysmal subarachnoid hemorrhage
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Men with aneurysmal subarachnoid hemorrhage
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Women and men
Number of subjects: 906
Study: 1505608

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 27

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 27
Study: 6407429

Group type: EXPERIMENTAL
Intervention: 40 mg slow release isosorbide dinitrate (ISDN group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5 mg slow release nitroglycerin (NTG group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 30
Study: 31926465

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 239
Study: 30071855

Group type: EXPERIMENTAL
Intervention: Family-based intervention using social media and face-to-face sessions (REDUCE programme)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 134
Study: 27184785

Group type: EXPERIMENTAL
Intervention: Ibuprofen IR/ER
Number of subjects: 654
Study: 24816453

Group type: EXPERIMENTAL
Intervention: Tai Chi (TCC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No Exercise Habit (NEH)
Number of subjects: 32
Study: 22371525

Group type: EXPERIMENTAL
Intervention: Daily electronic transmission of body weight to HF clinic using an electronic scale.
Number of subjects: 319
Study: 20065886

Group type: EXPERIMENTAL
Intervention: Laser acupoint stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (laser off)
Number of subjects: 40
Study: 18158500

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 4731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study: 15699284

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy with tamoxifen
Number of subjects: 5408
Study: 12818947

Group type: EXPERIMENTAL
Intervention: Propofol (100-200 micro g x kg(‐1) x min(‐1)) with 60% N(2)O in O(2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane (end-tidal concentration 0.8%) with 60% N(2)O in O(2)
Number of subjects: 60
Study: 11905407

Group type: EXPERIMENTAL
Intervention: Preoperative selective gut decontamination (SGD) with oral nonabsorbable antibiotics (polymyxin B and neomycin) for 5 to 7 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Preoperative selective gut decontamination (SGD)
Number of subjects: 78
Study: 10468001

Group type: EXPERIMENTAL
Intervention: Bovine whey protein fortifier
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ultrafiltrated human milk protein
Number of subjects: 32
Study: 8751020

Group type: EXPERIMENTAL
Intervention: Oral atropine (0.03 mg/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intramuscular atropine (0.02 mg/kg)
Number of subjects: 7
Study: 2096742

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine 1/200,000 epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lidocaine 1/100,000 epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine 1/200,000 epinephrine
Number of subjects: 0
Study: 7471712

Group type: EXPERIMENTAL
Intervention: Whole virus vaccine
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Experimental vaccine (A-EV)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Split vaccine
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Subunit vaccine
Number of subjects: 304
Study: 31163515

Group type: EXPERIMENTAL
Intervention: Self-affirmation writing exercises
Number of subjects: 562

Group type: COMPARATOR
Intervention: Control condition (neutral topic writing)
Number of subjects: 562
Study: 30865350

Group type: EXPERIMENTAL
Intervention: 2D image analysis tool for facial pore characterization
Number of subjects: 55
Study: 28630468

Group type: EXPERIMENTAL
Intervention: Neurofeedback training of P4 alpha activity for two days
Number of subjects: 0
Study: 25776198

Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping (ARM) procedure
Number of subjects: 265

Group type: COMPARATOR
Intervention: Traditional axillary lymph node dissection (ALND)
Number of subjects: 265
Study: 24074027

Group type: EXPERIMENTAL
Intervention: OCP (30 μg ethinyl E2/150 μg levonorgestrel) for 12-16 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: E2 valerate (4 mg/day) for 5-12 days
Number of subjects: 100
Study: 21377073

Group type: COMPARATOR
Intervention: Heine Classic+ Macintosh metal blades (Group M)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Vital View plastic blades (Group V)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Heine XP plastic blades (Group H)
Number of subjects: 519
Study: 19696205

Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT) program
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual hospital routine care (Control)
Number of subjects: 174
Study: 17414703

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) induction with steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) induction without steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG) induction (both groups)
Number of subjects: 0
Study: 15071483

Group type: EXPERIMENTAL
Intervention: Combined massage and physical activity (Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 30
Study: 11528581

Group type: EXPERIMENTAL
Intervention: Frequent monitoring (at baseline and every 2 months)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Infrequent monitoring (at baseline and twice yearly)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Frequent monitoring
Number of subjects: 206
Study: 9146258

Group type: EXPERIMENTAL
Intervention: Collaborative standardization of diagnosis and treatment of R/O sepsis patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative approach between nurses and physicians
Number of subjects: 0
Study: 8311073

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study: 3371082

Group type: EXPERIMENTAL
Intervention: 10 g or 10% fructose-1,6-diphosphate (FDP) twice daily for 7 to 10 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: saline
Number of subjects: 30
Study: 29661746

Group type: EXPERIMENTAL
Intervention: 200.000 IU vitamin D every 3 months
Number of subjects: 132

Group type: COMPARATOR
Intervention: 30.000 IU vitamin D every month
Number of subjects: 132
Study: 26952547

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg) plus oral prednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo plus oral prednisolone
Number of subjects: 30
Study: 23656601

Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET) - jaw movement exercise (JME)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET) - jaw movement exercise (JME) and psychological intervention (PI)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group - pharmacological treatment only
Number of subjects: 39
Study: 22573363

Group type: EXPERIMENTAL
Intervention: Catheter-based bilateral renal denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20379853

Group type: EXPERIMENTAL
Intervention: ezetimibe (E group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: orlistat (O group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: both ezetimibe and orlistat (OE group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 18355411

Group type: EXPERIMENTAL
Intervention: Korean pine nut FFA (3 g)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Korean pine nut TG (3 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 18
Study: 15735101

Group type: EXPERIMENTAL
Intervention: Soy protein (26.6 +/- 4.5 g protein/d containing 44.4 +/- 7.5 mg isoflavones/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soy protein + probiotics (10^9 colony-forming units Lactobacillus acidophilus DDS(R)+1 & Bifidobacterium longum, 15-30 mg fructooligosaccharide/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milk protein (26.6 +/- 4.5 g protein/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milk protein + probiotics
Number of subjects: 40
Study: 15532128

Group type: EXPERIMENTAL
Intervention: Institutionalized group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Never-institutionalized group
Number of subjects: 0
Study: 10780953

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (EPI) at 0.1 microg x kg(‐1) x min(‐1) from 30 to 40 min
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON) without epinephrine infusion
Number of subjects: 7
Study: 8831469

Group type: EXPERIMENTAL
Intervention: Persons with SCI
Number of subjects: 167

Group type: COMPARATOR
Intervention: Age- and sex-matched control group from the general population
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 167
Study: 1310159

Group type: EXPERIMENTAL
Intervention: Streptozocin plus doxorubicin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Streptozocin plus fluorouracil
Number of subjects: 105

Group type: COMPARATOR
Intervention: Chlorozotocin alone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Crossover therapy after failure of chlorozotocin or combination regimens
Number of subjects: 105
Study: 4077362

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (cyclo-oxygenase-inhibiting drug)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 6
Study: 3688595

Group type: EXPERIMENTAL
Intervention: Super-Char (57.76% reduction in aspirin absorption)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Actidose-Aqua (50.42% reduction in aspirin absorption)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Insta-Char (39.55% reduction in aspirin absorption)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Liqui-Char (33.40% reduction in aspirin absorption)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acta-Char (27.46% reduction in aspirin absorption)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control phase (baseline aspirin absorption with 2,592 mg aspirin)
Number of subjects: 7
Study: 31408152

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) services
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Availability of first and second line antiretroviral (ARV) medication
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clinical consultations
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patient compliance with drug use
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients' knowledge of HIV/AIDS transmission prevention
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quality of ART services
Number of subjects: 21
Study: 28451891

Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavior Therapy (ABBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 34
Study: 26112656

Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol 5/5 µg
Number of subjects: 5162

Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol 2.5/5 µg
Number of subjects: 5162

Group type: COMPARATOR
Intervention: Olodaterol 5 µg
Number of subjects: 5162

Group type: COMPARATOR
Intervention: Tiotropium 5 µg
Number of subjects: 5162
Study: 22930151

Group type: EXPERIMENTAL
Intervention: VEGF‐A assay
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CA‐125 assay
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: VEGF‐A level post-operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CA‐125 level post-operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of VEGF‐A and CA-125
Number of subjects: 60
Study: 22019148

Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham injections (dilute blood)
Number of subjects: 48
Study: 18631346

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with grass pollen extract
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 16461190

Group type: EXPERIMENTAL
Intervention: Systolic BP increase (10 mm Hg)
Number of subjects: 53163

Group type: EXPERIMENTAL
Intervention: Diastolic BP increase (10 mm Hg)
Number of subjects: 53163

Group type: COMPARATOR
Intervention: Systolic BP compared to pulse pressure and mean arterial pressure
Number of subjects: 53163
Study: 12006900

Group type: EXPERIMENTAL
Intervention: Imipramine maintenance treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo substitution
Number of subjects: 51
Study: 10211147

Group type: EXPERIMENTAL
Intervention: Olanzapine (n = 513)
Number of subjects: 1714

Group type: COMPARATOR
Intervention: Haloperidol (n = 114)
Number of subjects: 1714

Group type: COMPARATOR
Intervention: Haloperidol (n = 522)
Number of subjects: 1714
Study: 8529326

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole (derived from itraconazole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin 300 mg oral dose
Number of subjects: 0
Study: 2221962

Group type: EXPERIMENTAL
Intervention: MRI cranial scans (Group A)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: MRI spinal scans (Group B)
Number of subjects: 115

Group type: COMPARATOR
Intervention: CTM (Group B)
Number of subjects: 115
Study: 274992

Group type: EXPERIMENTAL
Intervention: BCG administered by the multiple-puncture technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no BCG)
Number of subjects: 12
Study: 31792893

Group type: EXPERIMENTAL
Intervention: Critical object looked at earlier and for longer when semantically unrelated to other objects in the display during target-present trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Critical object looked at earlier and for longer when semantically unrelated to other objects in the display during target-absent trials.
Number of subjects: 0
Study: 28569525

Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention (VetChange) for problem drinking
Number of subjects: 523
Study: 27590668

Group type: EXPERIMENTAL
Intervention: iPeer2Peer Program (intervention group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study: 25017001

Group type: EXPERIMENTAL
Intervention: Escitalopram (N=115)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Nortriptyline (N=126)
Number of subjects: 241
Study: 22494068

Group type: EXPERIMENTAL
Intervention: Gracey curettes with 15 vertical strokes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piezoceramic ultrasonic scaler with a power of 11
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piezosurgery ultrasonic scaler in mode ROOT with a power of two
Number of subjects: 20

Group type: COMPARATOR
Intervention: Termination diamond burs (40 μm) at 3000 r.p.m.
Number of subjects: 20
Study: 20018807

Group type: EXPERIMENTAL
Intervention: Hibiscus tea (3 240‐mL servings/d for 6 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 65
Study: 17767927

Group type: EXPERIMENTAL
Intervention: Removal of fillings (Group A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Removal and non-specific detoxification (Group B)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined groups A+B
Number of subjects: 82

Group type: COMPARATOR
Intervention: Health promotion program without removal (Group C)
Number of subjects: 82
Study: 16556720

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study: 12903044

Group type: EXPERIMENTAL
Intervention: HLA‐DRB1 low resolution typing
Number of subjects: 2810

Group type: EXPERIMENTAL
Intervention: HLA‐DRB1 high resolution typing by polymerase chain reaction‐sequence specific primers technique
Number of subjects: 2810
Study: 10668524

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study: 8912488

Group type: EXPERIMENTAL
Intervention: Anticonvulsive treatment with carbamazepine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 91
Study: 1672512

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 7257029

Group type: EXPERIMENTAL
Intervention: Low-dose heparin therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31806614

Group type: EXPERIMENTAL
Intervention: TALI Train (intervention group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80